Go to homepage
Shopping cart USD$0.00*
Show all categories SK-MEL Cells in Immunotherapy Response Prediction Back

SK-MEL Cells in Immunotherapy Response Prediction

The immunotherapy revolution has transformed melanoma treatment, with checkpoint inhibitors achieving durable responses in a significant subset of patients. At Cytion, we recognize that predicting which patients will respond to immunotherapy remains a critical challenge, requiring robust preclinical models that recapitulate tumor-immune interactions. SK-MEL melanoma cell lines provide essential platforms for studying the molecular determinants of immunotherapy response and identifying biomarkers that can guide patient selection for these transformative treatments.

Key Takeaways

  • SK-MEL lines display variable PD-L1 expression influencing checkpoint inhibitor response
  • Tumor mutational burden and neoantigen presentation correlate with immunogenicity
  • Co-culture systems with immune cells enable functional assessment of anti-tumor immunity
  • Interferon-gamma signaling pathway integrity predicts immunotherapy sensitivity
  • Resistance mechanisms including antigen presentation defects can be modeled in vitro
SK-MEL Cells in Immunotherapy Research SK-MEL Panel SK-MEL-1: BRAF WT SK-MEL-2: NRAS mut SK-MEL-5: BRAF V600E SK-MEL-28: BRAF V600E SK-MEL-29.1: Resistant Variable PD-L1/HLA Immune Checkpoint Axis SK-MEL PD-L1+ T Cell PD-1+ Inhibitory signal → Blocked by anti-PD-1 Response Biomarkers • PD-L1 expression level • Tumor mutational burden • Neoantigen load • HLA class I expression • IFN-γ pathway status • β2-microglobulin intact Immunotherapy Resistance Mechanisms HLA Loss/Downreg β2M Mutations JAK1/2 Mutations IFN-γ Insensitivity Co-Culture Assay Systems • SK-MEL + PBMC co-cultures • Tumor-reactive T cell killing • IFN-γ/Granzyme B release • Real-time cytotoxicity (xCELLigence) Combination Strategies • Anti-PD-1 + Anti-CTLA-4 • Checkpoint + BRAF/MEK inhibitor • ICI + oncolytic virus • ICI + radiation therapy © Cytion - Enabling Melanoma Immunotherapy Research

The SK-MEL Melanoma Cell Line Panel

The SK-MEL series encompasses multiple melanoma cell lines derived from different patients and metastatic sites, providing a diverse panel for studying immunotherapy response heterogeneity. These lines differ in their driver mutations, immune marker expression, and sensitivity to both targeted and immune-based therapies.

Our SK-MEL-28 Cells (300337) harbor the BRAF V600E mutation found in approximately 50% of melanomas. This line expresses moderate PD-L1 levels and has been extensively used to study the interaction between BRAF-targeted therapy and immunotherapy.

SK-MEL-5 Cells (300157) similarly carry BRAF V600E but display distinct immunological properties, enabling comparative studies of how genetic background influences immune recognition. The SK-MEL-1 Cells (300424) and SK-MEL-2 Cells (300423) represent BRAF wild-type melanomas with different NRAS status.

For broader melanoma research, our A375 Cells (300110) provide an additional BRAF-mutant model with well-characterized immunological properties.

PD-L1 Expression and Checkpoint Blockade Response

Programmed death-ligand 1 (PD-L1) expression on tumor cells serves as a key biomarker for checkpoint inhibitor response, though its predictive value is imperfect. SK-MEL lines exhibit variable constitutive PD-L1 expression that can be further induced by interferon-gamma, mimicking the adaptive immune resistance mechanism observed in patient tumors.

Flow cytometry quantification of surface PD-L1 enables characterization of expression levels across SK-MEL lines. Constitutive expression varies from low to moderate, with IFN-γ treatment (10-50 ng/mL for 24-48 hours) dramatically upregulating PD-L1 in responsive lines.

PD-L1 inducibility by IFN-γ indicates intact interferon signaling, which correlates with checkpoint inhibitor sensitivity. Lines with defective JAK-STAT signaling show impaired PD-L1 induction and often exhibit immunotherapy resistance, modeling a clinically relevant resistance mechanism.

Tumor-Immune Co-Culture Systems

Functional assessment of anti-tumor immunity requires co-culture systems that enable interaction between SK-MEL cells and immune effectors. Peripheral blood mononuclear cells (PBMCs) or purified T cell populations can be co-cultured with melanoma cells to assess immune-mediated killing.

Cytotoxicity assays quantify T cell killing of SK-MEL targets through various readouts including chromium release, lactate dehydrogenase (LDH) release, or real-time impedance monitoring. Checkpoint antibodies added to these co-cultures can enhance T cell cytotoxicity, providing functional validation of PD-1/PD-L1 axis blockade.

Cytokine release assays measure IFN-γ, TNF-α, granzyme B, and perforin secretion by T cells upon co-culture with SK-MEL cells. Enhanced cytokine production indicates productive T cell activation that may predict in vivo immunotherapy response.

Three-dimensional spheroid co-cultures better model the tumor microenvironment, incorporating spatial constraints that influence T cell infiltration and killing. SK-MEL spheroids co-cultured with T cells enable visualization of immune cell penetration and target cell killing within tumor-like structures.

Antigen Presentation and Neoantigen Recognition

Effective anti-tumor immunity requires tumor cell recognition through major histocompatibility complex (MHC) presentation of tumor antigens to T cells. SK-MEL lines vary in HLA class I expression, directly impacting immune recognition and checkpoint inhibitor response.

HLA typing and expression analysis characterize the antigen presentation capacity of each SK-MEL line. Loss of HLA class I through genetic alterations (β2-microglobulin mutations, HLA gene deletions) or epigenetic silencing represents a common immunotherapy resistance mechanism that can be modeled using specific SK-MEL lines.

Neoantigen prediction algorithms analyze the mutational landscape of SK-MEL lines to identify potential tumor-specific antigens. Lines with higher mutational burden generally harbor more neoantigens, correlating with enhanced immunogenicity and checkpoint inhibitor response.

Modeling Resistance Mechanisms

Understanding immunotherapy resistance is essential for developing strategies to overcome treatment failure. SK-MEL cells can be used to model both primary and acquired resistance mechanisms.

JAK1/2 mutations disrupt IFN-γ signaling essential for PD-L1 induction and T cell-mediated killing. SK-MEL lines with engineered JAK mutations model this resistance mechanism and enable screening for strategies to restore sensitivity.

β2-microglobulin loss eliminates surface HLA class I expression, rendering tumor cells invisible to cytotoxic T cells. This mechanism occurs in approximately 30% of immunotherapy-resistant melanomas and can be modeled through CRISPR knockout in SK-MEL lines.

Recommended Products for Melanoma Immunotherapy Research:

This website uses cookies to ensure you get the best experience on our website... More information.
- Imprint

We have detected that you are in a different country or are using a different browser language than currently selected. Would you like to accept the suggested settings?

Close